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Abstract A suspicious white powder labeled “idanyl-biphenyl-amninone”, which was 
seized by customs at the “channel island” of Jersey, UK, was brought to our laboratory 
to identify and characterize its structure. For the elucidation process it required the use 
of several complementary analytical techniques, such as gas chromatography-mass 
spectrometry, liquid chromatography coupled to high-resolution mass spectrometry, 
nuclear magnetic resonance spectroscopy, and X-ray crystallography. The unknown 
compound was finally identified as 1-(2,3dihydro-1H-inden-5-yl)-2-phenyl-2-
(pyrrolidin-1-yl)-ethanone, a novel cathinone derivative. To the best of our knowledge 
this compound has not been registered in the CAS or IUPAC database. However it has 
recently been marketed on the internet as “indapyrophenidone” and we therefore 
propose this as common name of the compound. The results of this study may serve 
forensic and clinical laboratories to identify its related compounds with similar 
backbone structure by using the information reported in this article by applying the 
advanced analytical techniques. It may also lead to timely and adequate responses by 
legislators and law enforcement in the near future. 
 
Keywords New psychoactive substances • Novel cathinone derivative • 1-(2,3dihydro-
1H-inden-5-yl)-2-phenyl-2-(pyrrolidin-1-yl)-ethanone • indapyrophenidone • High-
resolution mass spectrometry • Nuclear magnetic resonance spectroscopy • X-ray 
crystallography 
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Introduction 
 
The increase in the number, type and availability of new psychoactive substances 
(NPSs) with possible health and social risks is of alarming concern [1]. NPSs often have 
only minor modifications to the backbone structure of existing substances and many of 
them are designed and intended as legal replacement of conventional illicit drugs like 
cocaine, cannabis, and amphetamines. They produce similar effects. Although there is 
usually little or no information on their acute and particularly chronic harm, several 
intoxications and deaths have been reported [1, 2].  
In 2014, 101 NPSs were detected for the first time in the European Union (EU), 
and they were mostly synthetic cannabinoids, stimulants, hallucinogens and opioids. 
Thirty-one of these substances were synthetic cathinones, the largest class of new drugs 
identified in Europe in 2014.  In 2013, over 10,000 seizures of synthetic cathinones 
were reported to the EU Early Warning System. The cathinones are misused in similar 
ways to other stimulants such as amphetamine and MDMA [3, 4]. Since the mid-2000s, 
many ring-substituted cathinone derivatives have been sold on the recreational market 
usually as highly pure white or brown powders, but little is known of their detailed 
pharmacology [5]. With the communication facilities nowadays available, these new 
drugs may spread rapidly worldwide [1]. However, there is little knowledge on these 
new substances and they normally get missed in routine drug analysis [6], putting users 
at risk when abusing them. In addition, users often take new substances unknowingly, 
as branded products change their ingredients over time or vendors mislabel products to 
be able to sell out their stock. For analytical chemists and clinical toxicologists it 
becomes more and more difficult to keep their analytical screening methodologies up to 
date, due to the rapid introduction of new substances. Moreover, the detection and 
identification of NPSs is time consuming, complex and expensive. Nevertheless, it is an 
essential and first step to assess the risks, and ultimately to control potentially 
dangerous new drugs [7].  
A good analytical strategy is needed for detecting and identifying NPSs. The 
absence of reference standards and the limited availability of NPSs, both in terms of 
sample amount and/or purity, makes this task increasingly challenging. For these 
reasons, the combination of spectroscopic and mass spectrometric techniques is required 
for a true confirmation of the identity [8]. For example, the use of orthogonal 1D and 
2D NMR and mass spectrometric techniques represents a versatile approach that could 
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reach the sensitivity and structural detail required when unknown substances are to be 
detected or identified [9–11]. 
In this paper, we described the structure elucidation strategy, at our laboratory, 
for an unknown white powder labeled “idanyl-biphenyl-amninone”, seized by customs 
at the “channel island” of Jersey. Although Jersey is a self-governing parliamentary 
democracy, the United Kingdom (UK) is constitutionally responsible and therefore the 
unknown substance falls within its jurisdiction. Analysis of the unknown sample has 
been undertaken by combination of different spectroscopic techniques i.e. gas 
chromatography–mass spectrometry (GC–MS), liquid chromatography–quadrupole 
time-of-flight-mass spectrometry (LC–QTOF-MS), nulcear magnetic resonance (NMR) 
and finally X-ray crystallography. The aim of the present work was to identify and 
characterize the unknown substance and to provide analytical information regarding 
GC–MS, LC–QTOF-MS and NMR spectra. This information is important for forensic 
and clinical laboratories and allows tracking of possible further spreading of this NPS or 
potential derivatives worldwide.  
 
 
Material and methods  
 
Sample for analysis 
A white powder containing an unknown substance was obtained by customs of the 
island of Jersey (off the coast of Normandy, France) in 2014. 
 
Chemicals and reagents 
For GC–MS analysis, methanol, methyl-tert-butyl ether, quinoline and tripelennamine 
were purchased from Sigma-Aldrich (Madrid, Spain). For liquid chromatography–high 
resolution mass spectrometry (LC–HRMS) analysis, HPLC-grade water was obtained 
by purifying demineralised water in a Milli-Q plus system from Millipore (Bedford, 
MA, USA). HPLC-grade methanol (MeOH), formic acid (HCOOH) and sodium 
hydroxide (NaOH > 99%) were acquired from Scharlau (Barcelona, Spain). Leucine 
enkephalin was acquired also from Sigma-Aldrich. For NMR analysis, deuterated 
chloroform (CDCl3) was purchased from Sigma-Aldrich, and for X-ray diffraction, 
diethyl ether and acetonitrile were acquired from Scharlau.  
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Sample treatment  
Approximately 1 mg of powder was dissolved in 1 mL of methanol in 1.5 mL 
polypropylene tubes. The methanolic solutions were vortexed for 1 min and 
subsequently centrifuged at 8000 rpm (6030 g) for 5 min. For GC analysis, an aliquot of 
10 μL of the supernatant was diluted with 1 mL of methyl-tert-butyl ether, containing 
10 μg/mL quinoline and tripelennamine. For LC analysis, an aliquot of 100 μL of the 
supernatant was ten-fold diluted with water. For NMR analysis 10 mg of powder were 
dissolved in CDCl3, and suitable single crystals for X-ray diffraction analysis were 
obtained by slow vapor diffusion of diethyl ether into a saturated acetonitrile sample 
solution to obtain colorless needle-shaped single-crystals. 
 
Instrumentation 
GC–MS analyses with electron ionization (EI) were done using an Agilent 7890A GC 
with 5975C VL MSD (Agilent, Santa Clara, CA, USA) equipped with a split-splitless 
injector and an HP5-MS column (30 m length, 0.25 mm internal diameter, 0.25 μm film 
thickness) and running on Agilent ChemStation. A 1-μL aliquot of the diluted sample 
was injected for GC–MS analysis using 5:1 split ratio. The column was held at 80°C for 
4 min and then ramped up at 40°C/min to 290°C and held to a total run time of 40 min. 
A mass range of m/z 40 to 400 was scanned.  
For LC–QTOF-MS analysis, we used a Waters Acquity UPLC system (Waters, 
Milford, MA, USA) interfaced to a hybrid quadrupole-orthogonal acceleration-TOF 
mass spectrometer (XEVO G2 QTOF, Waters Micromass, Manchester, UK), using a Z-
Spray electrospray ionization (ESI) interface operating in positive ionization mode. The 
chromatographic separation was performed using an Acquity UPLC BEH C18 column 
(1.7 µm particle size, column 100 × 2.1 mm; Waters) at a flow rate of 300 µL/min. The 
mobile phases used were A = H2O and B = MeOH, both with 0.01% formic acid. MS 
data were acquired over therange m/z 50–1000. A capillary voltage of 0.7 kV was used. 
A cone voltage of 20 V was used. For further details, see our previous report [12].  
High-field 
1
H and 
13
C{
1
H} NMR analyses were recorded with Varian NMR 
System 500 MHz spectrometer at 303 K using CDCl3 (Varian, Palo Alto, CA, USA). 
The residual solvent signals [CHCl3 (
1H: δ = 7.26) and CDCl3 (
13C: δ = 77.16)] were 
6 
 
used as the internal references. Full characterization of the described compound was 
performed using gradient-enhanced two dimensional experiments: total correlated 
spectroscopy (TOCSY) and phase-sensitive hetero-nuclear single quantum coherence 
(HSQC) recorded under routine conditions using the Varian vnmrj2.2c software 
X-ray crystallography diffraction data were collected by using an Agilent 
Supernova diffractometer equipped with an Atlas CCD detector using CuKα radiation 
(λ= 1.54184 Å) at 293 K [13]. Data collection and integration was performed with the 
program SHELXS-2013 (Yale University, New Haven, CT, USA), using the OLEX 
software package (Olex AS, Trondheim, Norway).  
 
 
Results and discussion 
 
Gas chromatography – mass spectrometry  
First of all, we measured the total ion current chromatogram (TIC) of this sample by 
GC–MS. The TIC showed a single sharp peak, illustrating that the dubious powder 
consisted of a single compound with high purity (probably more than 95 %). GC–MS 
analysis is often used to identify drugs of abuse, as mass spectra searching can be used 
for GC–EI-MS using commercial or free standardized libraries (e.g. NIST, Cayman 
Spectral Library, SWGDrug GC-MS library). However, searching the obtained 
spectrum of the suspected compound in several forensic databases did not return any 
result. Nevertheless, some structural information was gained from the GC–MS 
measurements (Fig. 1), and together with the labeled name (“indanyl-biphenyl-
amninone”) of the powder, which might give some indications, the interpretation GC–
MS mass spectrum was done with great care.   
The GC–MS spectrum and the label suggested the presence of an indanyl group, 
possible next to a carbonyl and next to a nitrogen (indanyl-CO-NH-, m/z 160.1). A 
further loss of a CH group of this main ion, may result in an ion at m/z 146.  In addition, 
the presence of a phenyl- ring, linked by a carbon atom (C6H5-CH2-, m/z 91.1) i.e. a 
tropylium ion, can be assumed. Information on some functional groups, e.g. indanyl and 
a benzene group, was useful. However, for structure elucidation, additional analyses 
were necessary. 
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Liquid chromatography – quadrupole time of flight mass spectrometry  
LC–HRMS can provide the elemental composition based on the accurate-mass full-
acquisition data provided. The low fragmentation commonly ocurring in the soft 
ionization employed (i.e. ESI) favours the presence of the (de)protonated molecule in 
the mass spectra. The use of the hybrid QTOF analyzer makes it possible to perform 
additional tandem mass spectrometry analysis, obtaining the accurate-mass product ion 
mass spectra to be used in the elucidation process [14]. Information on the structure 
may be also obtained by applying strategies on the basis of mass-defect filtering or 
common fragmentation pathways [15, 16]. This, for example, helps to identify 
compounds, such as derivatives that share a common moiety. 
Fig. 2 shows the TIC, the corresponding accurate-mass spectrum and product 
ion mass spectra of the unknown substance generated by UHPLC–QTOF-MS. The 
retention time was 8.88 min (Fig. 2a) and the molecular formula was C21H23NO. The 
latter could be calculated with high confidence (mass error 0.6 ppm) from the accurate 
mass, m/z 306.1860, obtained for the protonated molecule [M+H]
+
 (Fig. 2b bottom). 
The elemental composition of the product ions was also estimated and the structures of 
most of them could be tentatively elucidated and explained by an initial neutral loss of a 
pyrrolidine C4H9N fragment, and subsequent loss of CO (Fig. 2b middle). At higher 
collision energy, two losses of CH3 radical and C2H4 were observed from fragment 
C16H15
+ 
with m/z 207.1174 (Fig. 2b top) that may intuitively come from the propylene 
group of the indanyl moiety. The unknown compound was tentatively identified as 1-
(2,3-dihydro-1H-inden-5-yl)-2-phenyl-2-(pyrrolidin-1-yl)-ethanone. Although it seemed 
feasible to explain the fragment C16H15
+
 from subsequent neutral losses of C4H9N and 
CO, some doubts were generated due to the major rearrangement needed to form this 
product ion (Fig. S1). Therefore, NMR analysis was performed to make the final 
elucidation of the structure of this compound. 
 
Nuclear magnetic resonance  
NMR is a powerful structure elucidation technique [17], and was used in the present 
work for further structure elucidation. The 
1
H NMR spectrum (500 MHz, CDCl3) of the 
unknown compound displayed partial signal overlapping both in the aliphatic and in the 
aromatic region (Fig. S2). The TOCSY and phase-sensitive HSQC spectra were 
particularly useful to unambiguously assign proton and carbon resonances. Figure 3 
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illustrates the TOCSY spectrum recorded in CDCl3, from which it can be inferred the 
presence of 4 spin systems and two isolated resonances. The pyrrolidine group (depicted 
in red in the online version) displayed two pairs of diastereotopic protons (manifested as 
4 equally populated broad resonances) in the δ = 3.2–3.8 ppm range, accompanied by a 
group of signals in the δ = 2.0–2.3 ppm range from the methylene groups at the 2 and 3 
pyrrolidine position. These signals were broad most likely due to the conformational 
exchange in the intermediate NMR time scale regime of the 5-membered pyrrolidine 
ring. Two resonances at δ = 2.0 and 2.8 ppm (marked in blue in the online version) with 
a 1:2 relative area were attributed to the propylene group from the indanyl moiety. Two 
additional equally populated resonances at δ = 7.2, 7.7 ppm were also detected from the 
trisubstituted phenyl ring group of the indanyl moiety (marked in pink in the online 
version). The single-substituted phenyl ring produced a set of signals at δ = 7.3 and 7.8 
ppm (depicted in green in the online version). Two isolated resonances, one at δ = 6.6 
ppm assigned to the CH neighbouring group to the carbonyl and the other overlapped 
with the single-substituted phenyl resonances, were also observed. The 
13
C NMR (125 
MHz, CDCl3) spectrum was consistent with the proposed structure (Fig. S3) and the 
phase-sensitive HSQC connectivities (Fig. S4) allowed the assignments of proton and 
carbon resonances to the structure of the sample. Two single carbon resonances (δ = 
23.9 and 52.7 ppm) for the methylene groups of the pyrrolidine at the 2 and 3 positions 
were observed. The propylene group of the indanyl moiety displayed three carbon 
resonances at δ = 25.2, 32.4 and 33.1 ppm, whereas the central quaternary carbon atoms 
of this fragment appeared in the usual δ =145–152 ppm range. The single-substituted 
phenyl group showed carbon resonances at the expected chemical shifts in the δ = 120 
to 130 ppm range, but most of them were partially overlapped with those from the CH 
groups of the indanyl framework (Fig. S3 and S4). The resonances for the isolated CH 
group neighbouring to the CO group and the CO group were observed at δ = 71.0 and 
192.1, respectively. 
 
X-ray crystallography 
X-ray crystallography was the ultimate confirmation step to establish the structure of 
the unknown substance. Diffraction data were collected by using an Agilent Supernova 
diffractometer equipped with an Atlas CCD detector. No instrument or crystal 
instabilities were observed during data collection. The structures were solved by charge-
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flipping methods by using Superflip and refined by the full-matrix method on the basis 
of F
2
 with the program SHELXL-2013, using the OLEX software package [18–20]. 
Absorption corrections based on the multiscan method were applied [21]. Details 
regarding the data collection and the refinement parameters used are listed in Table 
1.All non-hydrogen atoms were refined anisotropically and all the hydrogen atoms were 
included at their idealized positions and refined as riders with isotropic displacement 
parameters assigned as 1.2 times the Ueq value of the corresponding bonding partner.  
Suitable crystals for X-ray studies of the C21H24ClNO chloride protonated salt 
were grown by slow vapor diffusion of diethyl ether into a sample solution in 
acetonitrile. The structure of C21H23NO was refined in the non-centrosymmetric 
orthorhombic space group P212121 with cell dimensions: a = 7.1019(2), b = 16.0703(5), 
c = 16.1084(5) Å and α = β = γ = 90° (Table 1).  Figures 4 shows the ORTEP 
representation of the structure with the atom numbering scheme and selected average 
bond lengths. Chlorine atom of the counter anion was found disordered between two 
positions and occupation factors of the chlorine atoms were expressed in terms of a 
“free variable”, so that, their sum was constrained to 1. The flack parameter equal to 
0.42 indicates that this substance has crystallized with an excess of one enantiomer over 
the other due to the non-centrosymmetric character of the space group. The structural 
figure was drawn (Fig. 4) using Diamond (a visual crystal-structure-information 
software system) [22] and unambiguously confirmed 1-(2,3-dihydro-1H-inden-5-yl)-2-
phenyl-2-(pyrrolidin-1-yl)-ethanone to be the unknown compound. To the best of our 
knowledge this compound has not been registered in the CAS or IUPAC database. 
However it has recently been sold on the internet under the product name 
“indapyrophenidone”. 
Finally, all data regarding X-ray crystallography and structure refinement were checked 
and deposited in the Cambridge Crystallographic Data Centre. CCDC 1426092 contains 
the supplementary crystallographic data for this compound and can be obtained free of 
charge from CCDC via www.ccdc.cam.ac.uk/data_request/cif. 
 
 
Conclusions 
The identification and characterization of the unknown compound, identified as a novel 
cathinone derivative 1-(2,3-dihydro-1H-inden-5-yl)-2-phenyl-2-(pyrrolidin-1-yl)-
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ethanone, (C21H23NO) was an analytical challenge that required the complementary use 
of several advanced analytical techniques, including GC–MS, LC–HRMS, NMR and X-
ray crystallography. It was the first step required, which will allow controlling the 
possible consumption of this compound. Although the toxicity and pharmacological 
actions in human are unknown, it is expected that this compound exerts its psychoactive 
actions in humans that are similar to those of other cathinone derivatives. The strategy 
applied in this work can be used to identify other NPSs that continuously are appearing 
in the market. The analytical data obtained in this paper may contribute to the discovery 
of other potential cathinone derivatives. The presented information on the novel 
cathinone derivative will serve analytical chemists in forensic and clinical laboratories, 
toxicologists and other healthcare professionals.  
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Table 1 Crystallographic data for the unknown compound 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Data  
Empirical formula C21H24ClNO  
Formula weight 
 
341.86  
Temperature (K) 293(2)  
Crystal system 
 
Orthorhombic  
Space group P212121  
Unit cell dimensions   
a, Å 
 
7.1019(2)  
b, Å 
 
16.0703(5)  
c, Å 
 
16.1084(5)  
 90  


90  
 90  
Volume, Å3 
 
1838.45(10)  
Z 4  
Dcalc (Mg m
-3) 
 
1.235  
Absorption coeffient (mm–1) 
 
1.876  
F(000) 728.0  
Crystal size (mm3) 0.19 x 0.16 x 0.12  
Theta range for data collection (º) 3.89 to 66.95  
Index ranges -8 ≤ h ≤ 6,  
 -17 ≤ k ≤ 18,  
 -18 ≤ l ≤ 19  
Reflections collected 
 
8720  
Independent reflections 3130 [Rint = 0.0561]  
Absorption correction Multi-scan  
Refinement method Full-matrix least-squares on F2  
Data/restraints/parameters 3130/0/227  
Goodness-of-fit on F2 
 
1.110  
Final R indices [I>2(I)] 
 
R indices (all data) 
 
R1 = 0.0969, wR2 = 0.2675 
 
R1 = 0.1030, wR2 = 0.2747 
 
 
Largest difference in peak and hole (e·A–3) 
 
1.07 and –0.38  
Flack parameter 0.42(7)  
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Figure captions  
 
Fig. 1 Electron ionization mass spectrum of the unknown compound obtained by gas 
chromatography – mass spectrometry 
Fig. 2 Detection of the unknown compound by UHPLC– quadrupole time-of-flight-
mass spectrometry a total ion current chromatogram b full accurate-mass 
spectra applying collision energy of 4 eV (bottom), and tandem accurate-mass 
spectra applying collision energy of 20 and 30 eV (middle and top, 
respectively) 
Fig. 3 Total correlated spectroscopy (TOCSY) nuclear magnetic resonance spectrum of 
the unknown compound recorded in CDCl3 together with the proposed 
structure and proton signal assignments based on the chemical shift, signal 
intensities, multiplicity and connectivities derived from 
1
H TOCSY and 
phase-sensitive hetero-nuclear single quantum coherence experiments 
Fig. 4 Oak ridge thermal ellipsoid plot (ORTEP) X-ray crystallography presentation 
(ellipsoids at the 50 % probability level) of the unknown compound with 
atom numbering scheme. Selected bond lengths [Å]: N1–C1  1.519(9); N1–
C5 1.479(9); C5–C6 1.530(10); C5–C12 1.548(11); C12–O1 1.194(12); C12–
C13 1.493(12).  Hydrogen atoms have been omitted for clarity  
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Figure 4 
